SCHEMBL7529205

SCHEMBL7529205

CC(=NNC(=O)c1[nH]c2ccccc2c1C(C)C)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.50
RAB9A P51151 5/20 0.50
GAA P10253 1/20 0.50
CCNB2 O95067 1/20 0.47
CDK1 P06493 1/20 0.47
CCNB1 P14635 1/20 0.47
CCNB3 Q8WWL7 1/20 0.47
LMNA P02545 3/20 0.46
CYP1A2 P05177 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP2C9 P11712 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
PKM P14618 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA9 Q16790 1/20 0.45
RECQL P46063 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7558851 1.00 NPC1 (0.50) NPC1RAB9AGAACCNB2CDK1
SCHEMBL7561090 0.89 MAPT (0.50) NPC1RAB9ACYP1A2CYP2C19CYP2C9
SCHEMBL7561095 0.89 MAPT (0.50) NPC1RAB9ACYP1A2CYP2C19CYP2C9
SCHEMBL7559004 0.86 ALDH1A1 (0.53) NPC1RAB9AGAACYP1A2CYP2C19
SCHEMBL7559001 0.86 ALDH1A1 (0.53) NPC1RAB9AGAACYP1A2CYP2C19
SCHEMBL7561358 0.85 MAPT (0.52) NPC1RAB9AGAALMNASMN1; SMN2
SCHEMBL7561364 0.85 MAPT (0.52) NPC1RAB9AGAALMNASMN1; SMN2
SCHEMBL7561430 0.80 MAPT (0.61) NPC1RAB9AGAACCNB2CDK1
SCHEMBL7561436 0.80 MAPT (0.61) NPC1RAB9AGAACCNB2CDK1
SCHEMBL7535844 0.79 RAB9A (0.60) NPC1RAB9AGAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 NPC1 3749/4885RAB9A 3961/4885GAA 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.